0

Substrate-specific Effects of Pirinixic Acid Derivatives on ABCB1-mediated Drug Transport

Martin Michaelis, Florian Rothweiler, Mario Wurglics, Natália Aniceto, Michaela Dittrich, Heiko Zettl, Michael Wiese, Mark Wass, Taravat Ghafourian, Manfred Schubert-Zsilavecz, Jindrich Cinatl

Oncotarget. 2016 Mar 8;7(10):11664-76.

PMID: 26887049

Abstract:

Pirinixic acid derivatives, a new class of drug candidates for a range of diseases, interfere with targets including PPARα, PPARγ, 5-lipoxygenase (5-LO), and microsomal prostaglandin and E2 synthase-1 (mPGES1). Since 5-LO, mPGES1, PPARα, and PPARγ represent potential anti-cancer drug targets, we here investigated the effects of 39 pirinixic acid derivatives on prostate cancer (PC-3) and neuroblastoma (UKF-NB-3) cell viability and, subsequently, the effects of selected compounds on drug-resistant neuroblastoma cells. Few compounds affected cancer cell viability in low micromolar concentrations but there was no correlation between the anti-cancer effects and the effects on 5-LO, mPGES1, PPARα, or PPARγ. Most strikingly, pirinixic acid derivatives interfered with drug transport by the ATP-binding cassette (ABC) transporter ABCB1 in a drug-specific fashion. LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2μM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1. In silico docking studies identified differences in the interaction profiles of the investigated ABCB1 substrates with the known ABCB1 binding sites that may explain the substrate-specific effects of LP117. Thus, pirinixic acid derivatives may offer potential as drug-specific modulators of ABCB1-mediated drug transport.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1056468553 LP117 LP117 1056468-55-3 Price
qrcode